A study published in Annals of the Rheumatic Diseases was conducted to compare the efficacy and safety of brodalumab, an interleukin (IL) 17 receptor subunit A inhibitor, with placebo, in patients with psoriatic arthritis (PsA).
Adult patients with active PsA and inadequate response to, or intolerance to, conventional treatment were enrolled into two phase III studies (AMVISION-1and AMVISION-2). They were randomized 1:1:1 to receive subcutaneous brodalumab 140 mg, brodalumab 210 mg, or placebo at weeks 0, 1, and every 2 weeks up to 24 weeks. American College of Rheumatology (ACR) 20 response at week 16 was the primary endpoint.
A total of 962 patients were randomized across the two trials prior to early termination by the sponsor; however, the primary endpoint was met in both studies. Pooled data demonstrated that 45.8% and 47.9% of patients achieved ACR 20 at week 16 with brodalumab 140 mg and 210 mg, respectively, vs placebo (20.9%) (P<.0001). Analysis at week 24 revealed similar results. Patients who received brodalumab were significantly more likely to achieve ACR 50/70, Psoriasis Area and Severity Index 75/90/100, and resolution of dactylitis and enthesitis (P<.01). Adverse events were consistent across treatments at week 16 (54.4%, 51.6%, and 54.5% for placebo, brodalumab 140 mg and 210 mg, respectively), and no new safety signals were reported.
The study concluded that, based on the previous findings, brodalumab was associated with significant improvements in signs and symptoms of PsA and was well tolerated with a safety profile consistent with other IL-17 inhibitors. —Jessica Garlewicz
Â
Reference
Mease PJ, Helliwell PS, Hjuler KF, Raymond K, McInnes I. Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials. Ann Rheum Dis. 2021;80(2):185-193. doi:10.1136/annrheumdis-2019-216835
